Association between the timing of goals-of-care discussion and hospitalization outcomes in patients with metastatic cancer

OE Emiloju, DAM Djibo, JG Ford - American Journal of …, 2020 - journals.sagepub.com
Background: Patients with cancer often require acute hospitalizations, many of which are
unplanned. These hospitalizations have been shown to increase in frequency near the end of …

Neoadjuvant immune checkpoint inhibitor therapy for localized deficient mismatch repair colorectal cancer: a review

OE Emiloju, FA Sinicrope - JAMA oncology, 2023 - jamanetwork.com
Importance Colorectal cancers (CRCs) with deficient DNA mismatch repair (dMMR) account
for 15% of all CRCs. Deficient MMR is a predictive biomarker associated with …

Selecting Optimal First-Line Treatment for Microsatellite Stable and Non-Mutated RAS/BRAF Metastatic Colorectal Cancer

OE Emiloju, M Zhu, H Xie, Z Jin, FA Sinicrope… - … treatment options in …, 2023 - Springer
Opinion statement Standard frontline treatment of metastatic colorectal cancer (CRC) is
cytotoxic chemotherapy plus a biologic agent such as an anti-EGFR monoclonal antibody (…

[PDF][PDF] B-cell prolymphocytic leukemia: case report and challenges on a diagnostic and therapeutic forefront

BS Bindra, H Kaur, S Portillo, O Emiloju… - Cureus, 2019 - cureus.com
B-cell prolymphocytic leukemia (B-PLL) is a rare malignancy of mature B-cells with characteristic
morphologic, immunophenotypic, cytogenetic, and molecular features characterized by …

Synchronous Neoplasia Rates at Colonoscopic Diagnosis of Early-Onset vs Average-Onset Colorectal Cancer

OE Emiloju, B Saberzadeh-Ardestani… - JAMA Network …, 2023 - jamanetwork.com
Importance The incidence of early-onset colorectal cancer (CRC) (age, <50 years) continues
to increase globally within high-income countries. Objective To examine and compare rates …

Clinical Advancement and Challenges of ex vivo Expansion of Human Cord Blood Cells

OE Emiloju, R Potdar, V Jorge, S Gupta… - Clinical Hematology …, 2020 - Springer
Apart from peripheral blood stem cell (PBSC), umbilical cord blood (UCB) is now a recognized
source of stem cells for transplantation. UCB is an especially important source of stem …

Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort

OE Emiloju, J Yin, E Koubek, JM Reid, MJ Borad… - Investigational New …, 2024 - Springer
Navitoclax (ABT-263) is an oral BCL2 homology-3 mimetic that binds with high affinity to pro-survival
BCL2 proteins, resulting in apoptosis. Sorafenib, an oral multi kinase inhibitor also …

A retrospective study of circulating tumor DNA for minimal residual disease detection in the management of colorectal cancer.

MH Storandt, OE Emiloju, TJ Zemla, RR McWilliams… - 2023 - ascopubs.org
227 Background: Circulating tumor DNA (ctDNA) consists of small fragments of DNA
released into the plasma from cancer cells. Tumor informed ctDNA testing by whole exome …

Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer

OE Emiloju, M Storandt, T Zemla, N Tran… - JCO Precision …, 2024 - ascopubs.org
PURPOSE Recurrence after curative-intent treatment occurs in 20%-50% of patients with
stage II-IV colorectal cancer (CRC), underscoring the need for early detection of minimal …

[HTML][HTML] Hemophagocytic lymphohistiocytosis in an AIDS patient with Kaposi sarcoma: a treatment dilemma

OE Emiloju, S Gupta, V Arguello-Guerra… - Case Reports in …, 2019 - hindawi.com
Hemophagocytic lymphohistiocytosis (HLH) is a result of an abnormal activation of immune
cells (T lymphocytes, natural killer cells, and macrophages) resulting in cytokine …